SEC Form 4 · accession 0001140361-17-036526
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — EVP, Chief Commercial Officer
Period of report
Sep 22, 2017
Accepted (ET)
Sep 26, 2017 · 7:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 22, 2017 | M | 1,355 | $37.46 | A | 49,299 | D | |
| Common StockF1,F2 | Sep 22, 2017 | S | 1,355 | $95.00 | D | 47,944 | D | |
| Common StockF1 | Sep 22, 2017 | M | 2,166 | $37.46 | A | 50,110 | D | |
| Common StockF1,F2 | Sep 22, 2017 | S | 2,166 | $95.00 | D | 47,944 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F3 | $37.46 | Sep 22, 2017 | M | 1,355 | D | Nov 8, 2012 | May 7, 2022 | Common Stock | 1,355 | 2,166 | D |
| Stock Option (Right to buy Common Stock)F1,F3 | $37.46 | Sep 22, 2017 | M | 2,166 | D | Nov 8, 2012 | May 7, 2022 | Common Stock | 2,166 | 0 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on September 6, 2017.
- F2All shares were sold at the same price.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.